Form 4: PTC Therapeutics Director Exercises, Sells Shares

PTC Therapeutics Director Emma Reeve exercised stock options and immediately sold the acquired common stock on November 12, 2025, under a pre-arranged 10b5-1 plan.

Summary

• Emma Reeve, a Director at PTC Therapeutics, Inc., executed two transactions on November 12, 2025, pursuant to a Rule 10b5-1 plan adopted on March 4, 2025.
• She exercised stock options to acquire 7,333 shares of common stock at an exercise price of $46.54 per share.
• Immediately following the exercise, she sold all 7,333 shares of common stock at a price of $74.50 per share.
• The exercised options were granted on January 3, 2025, and vest over one year in twelve equal monthly installments, commencing on February 3, 2025.
• After these transactions, Reeve beneficially owns 6,666 shares of common stock and 1,467 stock options.

Sentiment

Score: 6

Explanation: The transactions represent a pre-planned exercise of options and subsequent sale of shares by a director, resulting in a profit for the insider. The execution under a Rule 10b5-1 plan suggests a systematic approach to managing equity rather than a direct signal of immediate market sentiment.

Positives

• The director realized a profit of $27.96 per share, totaling $205,090.68, by exercising options at $46.54 and selling the shares at $74.50.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, indicating a systematic approach to managing equity rather than a reaction to immediate market conditions.

Negatives

• A director selling shares, even under a pre-planned arrangement, reduces insider ownership, which some investors might interpret as a neutral to slightly negative signal.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The director's profitable sale of shares, while pre-planned, could be viewed neutrally to slightly negatively by some investors as it reduces insider ownership, though the 10b5-1 plan mitigates concerns about immediate sentiment.

Key Dates

Recommendation

The filing details a routine, pre-planned exercise of stock options and subsequent sale of shares by a director under a Rule 10b5-1 plan. While the director profited from the transaction, the pre-scheduled nature means it does not reflect new sentiment about the company's immediate prospects. It's a standard equity management event for an insider, providing no strong buy or sell signal for the stock based solely on this filing.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Stock Option Exercise, Share Sale, Director Transaction, Rule 10b5-1 Plan, Emma Reeve